ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,183.37
-0.87%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Olema Pharmaceuticals Inc (OLMA)

  7. Olema Pharmaceuticals Inc (OLMA) Noticias

OLMA Olema Pharmaceuticals Inc

9.48
-0.35 (-3.56%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Olema Pharmaceuticals Inc OLMA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.35 -3.56% 9.48 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.87 9.51 10.09 9.95 9.83
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202415:30GLOBEOlema Oncology to Participate in Canaccord Genuity 2024..
02/4/202415:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
11/3/202415:31EDGAR2Form S-8 - Securities to be offered to employees in employee..
11/3/202415:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11/3/202415:05EDGAR2Form 8-K - Current report
11/3/202415:03GLOBEOlema Oncology Reports Fourth Quarter and Full-Year 2023..
06/3/202406:03GLOBEOlema Oncology Announces Publication of Data Highlighting..
04/3/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
29/2/202413:26EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:08EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202411:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202416:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
06/2/202406:01GLOBEOlema Oncology to Participate in Upcoming Investor..
05/2/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:30GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/2/202414:24EDGAR2Form 144 - Report of proposed sale of securities
31/1/202415:21EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202413:58EDGAR2Form 144 - Report of proposed sale of securities
29/1/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202408:07EDGAR2Form 8-K - Current report
08/1/202407:18EDGAR2Form 8-K - Current report
08/1/202407:12GLOBEOlema Oncology Nominates OP-3136, an Orally Bioavailable..
05/1/202416:26EDGAR2Form 8-K - Current report
05/1/202416:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/1/202416:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:01GLOBEOlema Oncology to Present at 42nd Annual J.P. Morgan..
29/12/202314:54EDGAR2Form 144 - Report of proposed sale of securities
18/12/202317:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202316:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/12/202319:30EDGAR2Form 3/A - Initial statement of beneficial ownership of..
06/12/202306:48EDGAR2Form 8-K - Current report
05/12/202316:15EDGAR2Form 8-K - Current report
05/12/202311:27GLOBEOlema Oncology Announces Palazestrant Demonstrates..
04/12/202315:29GLOBEOlema Oncology Reports Inducement Grants Under Nasdaq..
01/12/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202309:20EDGAR2Form 144 - Report of proposed sale of securities
28/11/202316:10GLOBEOlema Oncology to Present New Palazestrant Clinical Data in..
22/11/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202314:25EDGAR2Form 144 - Report of proposed sale of securities
22/11/202314:04EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
OLMA
Olema Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados